Enveric Biosciences, Inc.

NasdaqCM:ENVB Stock Report

Market Cap: US$5.3m

Enveric Biosciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Enveric Biosciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Jul 02

An Intrinsic Calculation For Enveric Biosciences, Inc. (NASDAQ:ENVB) Suggests It's 40% Undervalued

Key Insights The projected fair value for Enveric Biosciences is US$0.98 based on 2 Stage Free Cash Flow to Equity...
Seeking Alpha • Jul 25

Enveric Biosciences to raise $8M in stock offering for corporate use

Enveric Biosciences (NASDAQ:ENVB) announced Monday the direct stock offering to raise up to $8M priced at-the-market. This includes registered direct offering to issue 375,000 shares along with preferred investment options to purchase up to 375,000 additional shares at a combined price of $8 per unit. And a private placement for 625,000 shares in addition of preferred investment options to purchase up to 625,000 more shares at the same $8 apiece. The preferred investment options have an exercise price of $7.78 per share. The company said it intends to use the net proceeds from the offerings for working capital and general corporate purposes. Closing of the offering is expected on July 26, 2022. Also, Enveric amends the exercise price of some of its existing warrants' to $7.78 each down from initial $27.50 per share. It holds the option to purchase up to an aggregate of 122,000 shares of common stock. ENVB shares fell 22% premarket. Earlier: Enveric to spin out cannabinoid pipeline into a public company

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enveric Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:ENVB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026N/A-12-8-8N/A
12/31/2025N/A-12-8-8N/A
9/30/2025N/A-11-8-8N/A
6/30/2025N/A-10-7-7N/A
3/31/2025N/A-9-8-8N/A
12/31/2024N/A-10-8-8N/A
9/30/2024N/A-10-8-8N/A
6/30/2024N/A-11-10-10N/A
3/31/2024N/A-15-12-12N/A
12/31/2023N/A-17-14-14N/A
9/30/2023N/A-23-16-16N/A
6/30/2023N/A-23-18-18N/A
3/31/2023N/A-19-18-18N/A
12/31/2022N/A-19-18-17N/A
9/30/2022N/A-52-19-18N/A
6/30/2022N/A-52-16-15N/A
3/31/2022N/A-50-14-13N/A
12/31/2021N/A-49-12-11N/A
9/30/2021N/A-11-10-10N/A
6/30/2021N/A-9-9-8N/A
3/31/2021N/A-9-7-6N/A
12/31/2020N/A-7-4-4N/A
9/30/2020N/A-3-2-2N/A
6/30/2020N/A-3-1-1N/A
3/31/2020N/A-3-1-1N/A
12/31/2019N/A-2N/A-1N/A
9/30/2019N/A-3N/A-1N/A
12/31/2018N/A-2N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ENVB's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if ENVB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ENVB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ENVB's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ENVB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ENVB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 09:32
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enveric Biosciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vernon BernardinoH.C. Wainwright & Co.